Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)

checkorphan
Learn more about:
X-linked adrenoleukodystrophy
Related Access Program
University of Minnesota – Clinical and Translational Science Institute – X-linked Adrenoleukodystrophy
Related Clinical Trial
SMART-ALD – A New Lifestyle Intervention to Improve Quality of Life in Women With X-linked Adrenoleukodystrophy (X-ALD) Quality of Life in Women With X-linked Adrenoleukodystrophy A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT) Plasma Exchange With Albumin in AMN Patients Stem Cell Transplant for Inborn Errors of Metabolism Human Placental-Derived Stem Cell Transplantation Precision Exercise in Children With Malignant Hemopathies Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy MD1003-AMN MD1003 in Adrenomyeloneuropathy A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients. Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD) A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy Repetitive Transcranial Magnetic Stimulation as Therapy in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy Clinical Study and Gene Mutation Analysis of Adrenoleukodystrophy in Taiwanese Children Early Diagnosis Of Childhood Cerebral ALD Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy Multi-center Clinical Study on the Diagnosis and Treatment Management of Rare Neurological Disease in Children HSCT for High Risk Inherited Inborn Errors Longitudinal Natural History Study of Patients With Peroxisome Biogenesis Disorders (PBD) UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD) A Phase III Trial of Lorenzo’s Oil in Adrenomyeloneuropathy Lentiviral Gene Therapy for X-ALD MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD) Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD) Newborn Screening for Adrenoleukodystrophy A Study to Prospectively Assess Disease Progression in Male Children With X-ALD Long-term Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy Expanded Access for Lorenzo’s Oil (GTO/GTE) in Adrenoleukodystrophy Minnesota Adrenoleukodystrophy Registry Study (MARS) and Biobank A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy

Brief Title

Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)

Official Title

A Prospective and Retrospective Data Collection Study to Evaluate Outcomes in Males ≤17 Years of Age Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Cerebral Adrenoleukodystrophy

Brief Summary

      Study ALD-103 will be a multi-site, global, prospective and retrospective data collection
      study that is designed to evaluate outcomes of allo-HSCT in male subjects with CALD ≤17 years
      of age.

Study Type

Observational

Primary Outcome

Incidence of transplant-related mortality (TRM).

Secondary Outcome

 Incidence of Major Functional Disabilities (MFDs).

Condition

X-Linked Adrenoleukodystrophy (X-ALD)

Intervention

Allo-HSCT

Study Arms / Comparison Groups

 Allo-HSCT prospective
Description:  Subjects who will be consented before they received an allo-HSC infusion. They will be consented and enrolled on the study during the Screening Period.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Genetic

Estimated Enrollment

59

Start Date

April 2015

Completion Date

December 6, 2019

Primary Completion Date

December 6, 2019

Eligibility Criteria

        Inclusion Criteria:

          1. Provide informed consent from a competent custodial parent or guardian with legal
             capacity to execute a local Institutional Review Board (IRB)/Independent Ethics
             Committee (IEC) approved consent. In addition, informed assent will be sought from
             capable subjects, in accordance with the directive of the institution's IRB/IEC and
             all other local requirements.

          2. Be male and ≤17 years of age at the time of treatment, for retrospective and partial
             prospective/retrospective subjects, or at the time of parental/guardian consent and,
             where appropriate, subject assent, for prospective subjects.

          3. Have a confirmed diagnosis of CALD as defined by abnormal VLCFA profile and cerebral
             lesion on brain MRI.

          4. Depending on the cohort, the subject must:

               -  Be scheduled for allo-HSCT evaluation at a study site (prospective cohort only),

               -  Have received an allo-HSC infusion and be consented in time to complete the Month
                  24 Visit on study (partial prospective/retrospective cohort only), or

               -  Have received their most recent allo-HSC infusion on or after January 1, 2013
                  (retrospective cohort only).

        Exclusion Criteria:

          1. Previous treatment with a gene therapy product.

          2. Receipt of an experimental transplantation procedure.

Gender

Male

Ages

N/A - 17 Years

Accepts Healthy Volunteers

No

Contacts

Elizabeth McNeil, MD MSc, ,

Location Countries

Argentina

Location Countries

Argentina

Administrative Informations

NCT ID

NCT02204904

Organization ID

ALD-103

Responsible Party

Sponsor

Study Sponsor

bluebird bio

Study Sponsor

Elizabeth McNeil, MD MSc, Study Director, bluebird bio, Inc.

Verification Date

December 2019